SEC Tracker
Get the app

MBX Biosciences MBX

MBX Biosciences Biosciences announces Q3 2026 results and trial updates

MBX Biosciences (MBX) filed an 8-K with the SEC on Nov 9, 2026, 4:06 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results, Item 7.01 Investor disclosure

Form
8-K
Filed
Importance
Major
  1. Cash and investments of $481.6 million expected to fund operations into 2029
  2. Pivotal Phase 3 oPTimize trial of once-weekly canvuparatide underway
  3. 12-week MAD data for MBX 4,291 on track for Q4 2026
  4. R&D expenses increased to $32 million in Q3 2026

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when MBX Biosciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.